Biotech Values

[DewDiligence]

Re: Future pricing of HCV interferons

So, ifn's double their price [to offset a shorter course of therapy].

The ifn vendors won’t be able to do that because there will continue to patients who undergo 48 weeks of therapy; these will include genotype-1/4 patients who fail to achieve RVR and (probably) all genotype-2/3 patients.